Skip to content
zameds

Biotin, folic acid, nicotinamide, pantothenic acid, pyridoxine, thiamine, vitamin b12, vitamin b2, vitamin c

Sold as Soluvit novum

Combination product

This product contains more than one active ingredient, so it has no single molecular structure.

Background

Loading...
Loading Wikipedia summary

Registration

Applicants
1
Registrations
1

Applicants and registrations

ApplicantBrandsDosagesRegistrationsScheduleLeaflets
Fresenius Kabi South Africa (Pty) LtdCertificate held by Fresenius Kabi South Africa (Pty) Ltd.Soluvit novum10 mlU0200Not determinedPIPIL

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Soluvit novum

EACH 10 ml VIAL CONTAINS BIOTIN 60 ug FOLIC ACID 0,4 mg NICOTINAMIDE 40 mg PANTOTHENIC ACID 15 mg PYRIDOXINE 4 mg THIAMINE HYDROCHLORIDE 3,2 mg VITAMIN B12 5 ug VITAMIN B2 3,6 mg VITAMIN C 100 mg

10 mlPowder for solution for infusion.U0200U/22.1.4/200Approved 3 February 2021RegisteredNot determinedPIPIL

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

  • S3: Vitamin b1

    • in preparations thereof for injection; (S0)
    • except in oral preparations or mixtures containing more than 100 mg of Vitamin B1 per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S1)

    Consolidated Schedules 06 July 2026, lines 4392 to 4397

  • S3: Vitamin b12

    • in preparations thereof for injection; (S0)
    • except in oral preparations or mixtures containing more than 100 µg of Vitamin B12 per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S1)

    Consolidated Schedules 06 July 2026, lines 4428 to 4433

  • S3: Vitamin b2

    • in preparations thereof for injection; (S0)
    • except in oral preparations or mixtures containing more than 100 mg of Vitamin B2 per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S1)

    Consolidated Schedules 06 July 2026, lines 4399 to 4404

  • S3: Vitamin b5

    • in preparations thereof for injection; (S0)
    • in oral preparations or mixtures containing more than 200 mg of Vitamin B5 per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S1)

    Consolidated Schedules 06 July 2026, lines 4414 to 4419

  • S3: Vitamin b6

    • in preparations thereof for injection; (S0)
    • except in oral preparations or mixtures containing more than 100 mg of Vitamin B6 per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S1)

    Consolidated Schedules 06 July 2026, lines 4421 to 4426

  • S3: Vitamin c

    • in preparations thereof for injection; (S0)
    • except in oral preparations or mixtures containing more than 1000 mg of Vitamin C per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S1)

    Consolidated Schedules 06 July 2026, lines 4435 to 4440

  • S1: Folic acid

    • in oral preparations or mixtures containing more than 500 µg of Folic Acid per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S0)

    Consolidated Schedules 06 July 2026, lines 484 to 485

  • S1: Nicotinamide

    • in oral preparations or mixtures containing more than 500 mg of Nicotinamide per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S0)

    Consolidated Schedules 06 July 2026, lines 886 to 888

  • S1: Vitamin b1

    • in oral preparations or mixtures containing more than 100 mg of Vitamin B1 per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0)
    • except in preparations thereof for injection. (S3)

    Consolidated Schedules 06 July 2026, lines 1149 to 1154

  • S1: Vitamin b12

    • in oral preparations or mixtures containing more than 100 µg of Vitamin B12 per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0)
    • except in preparations thereof for injection. (S3)

    Consolidated Schedules 06 July 2026, lines 1177 to 1182

  • S1: Vitamin b2

    • in oral preparations or mixtures containing more than 100 mg of Vitamin B2 per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0)
    • except in preparations thereof for injection. (S3)

    Consolidated Schedules 06 July 2026, lines 1156 to 1161

  • S1: Vitamin b5

    • in oral preparations or mixtures containing more than 200 mg of Vitamin B5 per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0)
    • except in preparations thereof for injection. (S3)

    Consolidated Schedules 06 July 2026, lines 1163 to 1168

  • S1: Vitamin b6

    • in oral preparations or mixtures containing more than 100 mg of Vitamin B6 per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0)
    • except in preparations thereof for injection. (S3)

    Consolidated Schedules 06 July 2026, lines 1170 to 1175

  • S1: Vitamin c

    • in oral preparations or mixtures containing more than 1000 mg of Vitamin C per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0)
    • except in preparations thereof for injection. (S3)

    Consolidated Schedules 06 July 2026, lines 1184 to 1189

  • S1: Vitamin h

    • in oral preparations or mixtures containing more than 500 µg of Vitamin H per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S0)

    Consolidated Schedules 06 July 2026, lines 1196 to 1197

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

SAHPRA documents

Professional information (PI)For healthcare professionalsSoluvit novum, Fresenius Kabi South Africa (Pty) LtdPatient information leaflet (PIL)For patients and carersSoluvit novum, Fresenius Kabi South Africa (Pty) Ltd

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Research articles

Loading...
Loading PubMed articles